

A market research report on

10 Healthcare Players aiming Beyond Health Equality to Conquer Health Equity




What would this Report Cover?

- 1. Health Equity: A Virtuous Cycle**
- 2. Factors Manifesting Health Equity**
- 3. Healthcare Players Aiming Healthcare Equity**
 - Bayer
 - Gilead
 - Sanofi
 - Bristol Myers Squibb
 - Johnson & Johnson
 - Merck
 - Pfizer
 - AstraZeneca
 - Takeda
 - Biogen

1. Health Equity: A Virtuous Cycle

Pharmaceutical and life sciences companies has unlocked new opportunities, help underserved patients, and build a cycle of trust to drive a virtuous cycle



1. Analyse (High Quality Data)

Consider the information and data we have now



2. Expand (Problem Solving)

Consider whose problems we have been solving



3. Challenge (Targeted Approaches)

Consider why some groups are not receiving the appropriate medicine or therapy at the right time




4. Engage (Better Collaboration)

Consider whom else we can collaborate with to fill the identified gaps, & how we can encourage more people to receive needed care

2. Factors Manifesting Health Equity

Intricately complicated health disorders can progress, and access disparities, unmet needs, or marginalized communities can all be signs of health inequities



3. Healthcare Players Aiming Healthcare Equity (1/5)



Bayer

- Bayer's U.S. business nabbed a perfect score from the Human Rights Campaign Foundation's Corporate Equality Index
- Helps boost the overall ranking from alva for the company, which also has a major focus on food and nutrition and agriculture
- Bayer also works with the new Women in STEM leadership pilot program across 12 countries that the Pistoia Alliance recently announced



Gilead

- Gilead repurposing Ebola drug remdesivir as the first treatment for COVID boosted its overall reputation last year
- Gilead launched Zeroing In: Ending the HIV Epidemic, which gifted \$24 million in grants to 116 organizations in 41 countries to tackle the problem on the ground
- The company wants to hire or promote 200 Black Americans without a four-year degree while also increasing Hispanic representation to 15% of its U.S. workforce and 3.7% of leadership roles and boosting female leadership representation to 39%

3. Healthcare Players Aiming Healthcare Equity (2/5)



Sanofi

- The Paris-based company has launched an Employee Resource Group (ERG) framework in which voluntary, employee-led ERGs will focus on five areas—gender, generations, pride, ability and culture and origins
- Sanofi's DE&I strategy 2025 goals revolve around three key pillars: building representative leadership, creating a work environment where employees can bring their whole selves and engaging with the company's diverse communities



Bristol Myers Squibb

- BMS has been at the forefront of the fight to boost diversity by issuing \$7.9Mn of health equity grants to 24 U.S. nonprofit organizations aimed at improving access and quality care to medically underserved patients and communities
- BMS until 2025 will accelerate five diversity and inclusion and health equity commitments—addressing disparities in healthcare, increasing diversity in clinical trials, expanding supplier diversity, enhancing employee giving to social justice organizations and increasing workforce representation

3. Healthcare Players Aiming Healthcare Equity (3/5)



Johnson & Johnson

- 2022 was Year 1 of the pharma's Health for Humanity 2025 plan
- The program comes with 20 key goals like boosting women in management, greater diversity in senior teams and improving health equity by developing treatments for underserved HIV and tuberculosis patient communities
- By 2025, the pharma has pledged to have 50% of management positions globally made up of women and also 35% ethnic/racial diversity in U.S. management positions

Merck

- To boost diversity in its clinical trials, Merck is working to build new partnerships with organizations like Black Health Matters, the National Urban League and the Lazarex Cancer Foundation
- The company granted voluntary licenses to several Indian generic manufacturers in an effort to boost the availability of molnupiravir in India and in other low- and middle-income countries
- Also teamed up with Johnson & Johnson to scale up production of J&J's single-shot COVID vaccine to help expand global access

3. Healthcare Players Aiming Healthcare Equity (4/5)



Pfizer

- Pfizer recently teamed up with trial site network Headlands Research to break ground on several new research sites in diversely populated areas. A new Headlands facility is set to take root in Brownsville, Texas—a city of about 180,000 on the border of Mexico
- Pfizer has joined the Paradigm for Parity coalition, aiming to achieve “full gender parity” by 2030, with a near-term goal of women holding at least 30% of senior roles

AstraZeneca

- The Anglo-Swedish Big Pharma's strategy includes two 2025 goals: to reach gender equality in management positions and to launch supplier diversity programs in 10 new countries outside the US
- AstraZeneca also participates in the Pistoia Alliance's new Women in STEM leadership pilot program to enable leadership and mentoring skill development while furthering workplace diversity

3. Healthcare Players Aiming Healthcare Equity (4/5)



Takeda

- Takeda launched the Center for Health Equity and Patient Affairs (HEPA) as a center of excellence in 2021 and hopes to make it a leader in health equity and patient centricity to “create a more inclusive ecosystem and strengthen trust and reputation with patients and other key external stakeholders around the world”
- Takeda is also looking to roll out an enterprise-wide Candidate Relationship Management tool connected with an Applicant Tracking System that it hopes will “create inclusive talent communities”



Biogen

- Biogen created a new four-point plan to focus on building a more diverse workforce “at all levels” as well as “building awareness, capability and a sustained urgency to act”

Who should buy this report?



Pharmaceutical
Players



Digital Health
Entities



HealthTech
Companies



MedTech
Players



Other Lifesciences
Companies



Cost of this report:
\$2,500

Annual Subscription:
~~*\$125,000*~~ *\$60,000*
(Includes a total of 50 reports)

 www.insights10.com

Topics of Upcoming Reports

- Will the Expiry of Humira Market Exclusivity and Entry of its Biosimilars Move the Needle in BioPharma Market?
- Metaverse: Paving the way for Health 4.0
- Patient Engagement- a New Standpoint on Care that is Patient-Centered
- E-Rx, the Digital Version of Prescription Improving the Chances of Better Patient Outcomes
- Integration of Healthcare Systems with Big Data and Data Silos

Methodology & Scope




Research Methodology


- Insights 10's research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive overview of the competitive landscape to help our clients make informed strategic decisions
- We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government and regulatory published material, technical journals, trade magazines, and paid data sources
- For forecasting, the following parameters are considered:
 - ❑ Market drivers and restraints along with their current and expected impacts
 - ❑ Technological scenario and expected developments
 - ❑ End use industry trends and dynamics
 - ❑ Trends in the consumer behavior
 - ❑ Regulatory scenario and expected developments
 - ❑ Current capacity and expected capacity additions up to 2030
- We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected market growth rate
- We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-sensitive, reflecting the most recent value and volume of the market across regions
- All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
- Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn)

Analysis Methodology

Our Analysis Methodology involves three critical stages:



Data Triangulation & Data Validation



Key Benefits for Stakeholders from this Report

- Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets
- Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and quantitative industry variables
- Comprehensive analysis of factors that drive and restrict the market growth is provided
- Comprehensive quantitative analysis of the industry from 2021 to 2030F is provided to enable the stakeholders to capitalize on the prevailing market opportunities
- Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
- Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors

Time Frame	Report Attribute	Details
<div style="display: flex; flex-direction: column; align-items: center;"> <div style="margin-bottom: 20px;"> <p>2021</p> <p>● Base Year for Estimation</p> </div> <div> <p>2022-2030</p> <p>● Forecast Period</p> </div> </div>	Quantitative Units	Revenue in USD Million/Billion (Mn/Bn)
	Report Coverage	Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Company Profiles, Competitive Landscape, Regulatory Landscape, Future Opportunities
	Customized Report	Report Customization (5 working days) with purchase. We will provide you with data that is currently not a part of our scope as a part of customization
	Pricing and purchase options	Avail customized purchase options to meet your exact research needs

Thank You for previewing this eBook

You can read the full version of this eBook in different formats:

- HTML (Free /Available to everyone)
- PDF / TXT (Available to V.I.P. members. Free Standard members can access up to 5 PDF/TXT eBooks per month each month)
- Epub & Mobipocket (Exclusive to V.I.P. members)

To download this full book, simply select the format you desire below

